Compare Moderna, Inc. (MRNA) vs NetFlix Inc (NFLX) Price & Performance

Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.

The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.

Netflix (NFLX) is trading at $76.03, down 2.84% on the day, amid a bearish technical signal and recent price weakness. The stock is near its 52-week low, with support at $76 and resistance at $78. Fundamentally, the company shows strong revenue growth, with 2025 revenue at $45.18 billion and net income of $10.98 billion, and has beaten EPS estimates for the last three quarters. Analyst sentiment remains largely positive with a consensus buy rating and price target of $88.95, though recent news highlights concerns over the stock's performance streak.

The outlook for NFLX is mixed; strong fundamentals and analyst optimism suggest potential upside, but technical bearishness and competitive pressures pose risks. Investors should weigh robust profitability and ad-tier expansion against market volatility and execution challenges in the streaming sector.